Oct 9, 2022Patients with positive peritoneal cytology for endometrial cancer have a high risk of recurrence, regardless of histopathologic type or FIGO IntroductionsMethodsResultsDiscussion
Patients with positive peritoneal cytology for endometrial cancer have a high risk of recurrence, regardless of histopathologic type or FIGO stage. Peritoneal cytology has already been removed from the 2009 FIGO classification of endometrial cancer, but it may deserve reconsideration.
Patients with positive peritoneal cytology for endometrial cancer have a high risk of recurrence, regardless of histopathologic type or FIGO stage.
Suspicious positive peritoneal cytology may be an
independent risk factor for endometrial cancer. The positive rate of peritoneal tumor cells in type II endometrial cancer is higher than other cells and is an independent risk factor for type II endometrial cancer.An estimated
11% of patients undergoing staging for endometrial cancer will have positive peritoneal cytology, most commonly in the presence of extra-uterine disease.2 The prognostic significance of isolated positive cytology in the absence of extra-uterine disease is controversial.
Positive peritoneal cytology (PPC) is of prognostic significance in patients with advanced-stage endometrial cancer that spreads to the adnexa, lymph nodes (LN) or peritoneum ( 1 ). However, the prognostic significance of isolated PPC in patients with early-stage endometrial cancer (EEC, Stage 1 or 2) is controversial ( 2–6 ).
Despite all previous investigations, the role of positive peritoneal cytology in endometrial cancer
staging is still a matter of debate, and excluding positive peritoneal cytology from the staging system may mislead prognosis estimations in these patients, resulting in under treatment and an increasing mortality rate (11).